SCHEMBL496141

SCHEMBL496141

COc1ccc(C(=O)O)c(NC2CCCCC2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
SYK P43405 2/20 0.42
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
RIPK1 Q13546 1/20 0.41
CTSL P07711 1/20 0.41
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
AXL P30530 1/20 0.41
MERTK Q12866 1/20 0.41
MAPK8 P45983 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
RAB9A P51151 1/20 0.40
CCR4 P51679 1/20 0.40
HCAR3 P49019 1/20 0.40
NNMT P40261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ROCK2 O75116 1/20 0.39
ROCK1 Q13464 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL496337 0.89 RIPK1 (0.49) POLBTDP1SYKRIPK1CTSL
SCHEMBL6644500 0.82 CHRM3 (0.44) SYKCNR1CNR2MERTKMAPK8
SCHEMBL495797 0.79 KMT2A (0.43) SYKCTSLCTSSCTSKMERTK
SCHEMBL496548 0.79 MAPK8 (0.43) SYKCTSLCTSSCTSKMERTK
SCHEMBL2344874 0.78 MAPK8 (0.40) SYKCTSLCTSSCTSKAXL
SCHEMBL4484697 0.75 HPGDS (0.54) POLBSYKCTSLCTSSCTSK
SCHEMBL19708805 0.75 TXNRD1 (0.58) TDP1RAB9ANPSR1
SCHEMBL4402475 0.74 SYK (0.45) SYKMERTKMAPK8HCAR3
SCHEMBL12936321 0.73 RIPK1 (0.49) TDP1SYKRIPK1AXLMERTK
SCHEMBL19706830 0.73 ALOX15 (0.46) AXLMERTKRAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 POLB 4665/4885TDP1 2716/4885SYK 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.